nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0272	0.0433	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0272	0.0433	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0235	0.0374	CbGbCtD
Risperidone—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0235	0.0374	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0228	0.0363	CbGbCtD
Risperidone—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0228	0.0363	CbGbCtD
Risperidone—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0226	0.0359	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0206	0.0328	CbGbCtD
Risperidone—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0206	0.0328	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0206	0.0328	CbGbCtD
Risperidone—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0206	0.0328	CbGbCtD
Risperidone—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0204	0.0325	CbGbCtD
Risperidone—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0204	0.0325	CbGbCtD
Risperidone—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0176	0.028	CbGbCtD
Risperidone—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0171	0.0272	CbGbCtD
Risperidone—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0155	0.0246	CbGbCtD
Risperidone—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0155	0.0246	CbGbCtD
Risperidone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0147	0.0234	CbGbCtD
Risperidone—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0147	0.0234	CbGbCtD
Risperidone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0139	0.022	CbGbCtD
Risperidone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0139	0.022	CbGbCtD
Risperidone—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0133	0.0211	CbGbCtD
Risperidone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0125	0.0199	CbGbCtD
Risperidone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0125	0.0199	CbGbCtD
Risperidone—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0115	0.0182	CbGbCtD
Risperidone—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0111	0.0177	CbGbCtD
Risperidone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0108	0.0172	CbGbCtD
Risperidone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0105	0.0167	CbGbCtD
Risperidone—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0101	0.016	CbGbCtD
Risperidone—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0101	0.016	CbGbCtD
Risperidone—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00966	0.0154	CbGbCtD
Risperidone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00949	0.0151	CbGbCtD
Risperidone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00949	0.0151	CbGbCtD
Risperidone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00937	0.0149	CbGbCtD
Risperidone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00881	0.014	CbGbCtD
Risperidone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00881	0.014	CbGbCtD
Risperidone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00797	0.0127	CbGbCtD
Risperidone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00797	0.0127	CbGbCtD
Risperidone—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00747	0.0119	CbGbCtD
Risperidone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00688	0.0109	CbGbCtD
Risperidone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00668	0.0106	CbGbCtD
Risperidone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00604	0.0096	CbGbCtD
Risperidone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00604	0.0096	CbGbCtD
Risperidone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00579	0.0092	CbGbCtD
Risperidone—H1F0—semen—acquired immunodeficiency syndrome	0.00453	0.0763	CbGeAlD
Risperidone—DRD1—nerve—acquired immunodeficiency syndrome	0.00215	0.0363	CbGeAlD
Risperidone—HTR7—nerve—acquired immunodeficiency syndrome	0.00135	0.0227	CbGeAlD
Risperidone—DRD2—nerve—acquired immunodeficiency syndrome	0.00127	0.0215	CbGeAlD
Risperidone—HTR7—endothelium—acquired immunodeficiency syndrome	0.00115	0.0193	CbGeAlD
Risperidone—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00106	0.018	CbGeAlD
Risperidone—HTR7—blood plasma—acquired immunodeficiency syndrome	0.00102	0.0172	CbGeAlD
Risperidone—H1F0—retina—acquired immunodeficiency syndrome	0.000903	0.0152	CbGeAlD
Risperidone—HTR2A—nerve—acquired immunodeficiency syndrome	0.000839	0.0142	CbGeAlD
Risperidone—H1F0—skin of body—acquired immunodeficiency syndrome	0.000793	0.0134	CbGeAlD
Risperidone—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000783	0.0132	CbGeAlD
Risperidone—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.000746	0.0126	CbGeAlD
Risperidone—DRD4—brain—acquired immunodeficiency syndrome	0.000736	0.0124	CbGeAlD
Risperidone—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000715	0.0121	CbGeAlD
Risperidone—DRD3—nervous system—acquired immunodeficiency syndrome	0.000676	0.0114	CbGeAlD
Risperidone—DRD3—central nervous system—acquired immunodeficiency syndrome	0.000651	0.011	CbGeAlD
Risperidone—H1F0—lymphoid tissue—acquired immunodeficiency syndrome	0.000642	0.0108	CbGeAlD
Risperidone—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000635	0.0107	CbGeAlD
Risperidone—H1F0—digestive system—acquired immunodeficiency syndrome	0.000634	0.0107	CbGeAlD
Risperidone—H1F0—blood—acquired immunodeficiency syndrome	0.000604	0.0102	CbGeAlD
Risperidone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000588	0.00991	CbGeAlD
Risperidone—H1F0—bone marrow—acquired immunodeficiency syndrome	0.000585	0.00986	CbGeAlD
Risperidone—H1F0—spinal cord—acquired immunodeficiency syndrome	0.000582	0.00982	CbGeAlD
Risperidone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000578	0.00975	CbGeAlD
Risperidone—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000571	0.00964	CbGeAlD
Risperidone—H1F0—vagina—acquired immunodeficiency syndrome	0.00056	0.00945	CbGeAlD
Risperidone—H1F0—lung—acquired immunodeficiency syndrome	0.00053	0.00893	CbGeAlD
Risperidone—DRD2—retina—acquired immunodeficiency syndrome	0.000527	0.00889	CbGeAlD
Risperidone—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.00052	0.00876	CbGeAlD
Risperidone—DRD3—brain—acquired immunodeficiency syndrome	0.000517	0.00872	CbGeAlD
Risperidone—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.0005	0.00844	CbGeAlD
Risperidone—H1F0—nervous system—acquired immunodeficiency syndrome	0.00049	0.00827	CbGeAlD
Risperidone—DRD1—nervous system—acquired immunodeficiency syndrome	0.000484	0.00817	CbGeAlD
Risperidone—H1F0—central nervous system—acquired immunodeficiency syndrome	0.000472	0.00797	CbGeAlD
Risperidone—DRD1—central nervous system—acquired immunodeficiency syndrome	0.000466	0.00787	CbGeAlD
Risperidone—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000466	0.00786	CbGeAlD
Risperidone—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000457	0.00771	CbGeAlD
Risperidone—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000447	0.00753	CbGeAlD
Risperidone—HTR2B—blood—acquired immunodeficiency syndrome	0.000435	0.00734	CbGeAlD
Risperidone—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000416	0.00702	CbGeAlD
Risperidone—HTR2B—vagina—acquired immunodeficiency syndrome	0.000404	0.00681	CbGeAlD
Risperidone—ADRA1B—brain—acquired immunodeficiency syndrome	0.000397	0.0067	CbGeAlD
Risperidone—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000392	0.00662	CbGeAlD
Risperidone—HTR7—digestive system—acquired immunodeficiency syndrome	0.000391	0.0066	CbGeAlD
Risperidone—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000382	0.00645	CbGeAlD
Risperidone—HTR2B—lung—acquired immunodeficiency syndrome	0.000382	0.00644	CbGeAlD
Risperidone—HTR1D—nervous system—acquired immunodeficiency syndrome	0.00038	0.00641	CbGeAlD
Risperidone—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000378	0.00637	CbGeAlD
Risperidone—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000376	0.00635	CbGeAlD
Risperidone—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000376	0.00634	CbGeAlD
Risperidone—H1F0—brain—acquired immunodeficiency syndrome	0.000375	0.00632	CbGeAlD
Risperidone—HTR7—blood—acquired immunodeficiency syndrome	0.000373	0.00629	CbGeAlD
Risperidone—DRD1—brain—acquired immunodeficiency syndrome	0.00037	0.00624	CbGeAlD
Risperidone—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000366	0.00617	CbGeAlD
Risperidone—H1F0—lymph node—acquired immunodeficiency syndrome	0.000362	0.00611	CbGeAlD
Risperidone—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000362	0.00611	CbGeAlD
Risperidone—ADRA1A—blood—acquired immunodeficiency syndrome	0.00036	0.00607	CbGeAlD
Risperidone—HTR7—spinal cord—acquired immunodeficiency syndrome	0.000359	0.00606	CbGeAlD
Risperidone—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000353	0.00596	CbGeAlD
Risperidone—HTR2A—retina—acquired immunodeficiency syndrome	0.000348	0.00586	CbGeAlD
Risperidone—KCNH2—blood—acquired immunodeficiency syndrome	0.000347	0.00586	CbGeAlD
Risperidone—ADRA2C—blood—acquired immunodeficiency syndrome	0.000343	0.00578	CbGeAlD
Risperidone—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.00034	0.00574	CbGeAlD
Risperidone—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000336	0.00567	CbGeAlD
Risperidone—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000335	0.00564	CbGeAlD
Risperidone—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.00033	0.00557	CbGeAlD
Risperidone—HTR7—lung—acquired immunodeficiency syndrome	0.000327	0.00551	CbGeAlD
Risperidone—KCNH2—vagina—acquired immunodeficiency syndrome	0.000322	0.00543	CbGeAlD
Risperidone—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000318	0.00536	CbGeAlD
Risperidone—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000317	0.00534	CbGeAlD
Risperidone—DRD2—lung—acquired immunodeficiency syndrome	0.000309	0.00521	CbGeAlD
Risperidone—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000305	0.00514	CbGeAlD
Risperidone—HTR7—nervous system—acquired immunodeficiency syndrome	0.000303	0.00511	CbGeAlD
Risperidone—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000301	0.00508	CbGeAlD
Risperidone—ADRA2C—lung—acquired immunodeficiency syndrome	0.0003	0.00507	CbGeAlD
Risperidone—HTR1B—brain—acquired immunodeficiency syndrome	0.0003	0.00506	CbGeAlD
Risperidone—HRH1—digestive system—acquired immunodeficiency syndrome	0.000292	0.00493	CbGeAlD
Risperidone—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000292	0.00492	CbGeAlD
Risperidone—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000291	0.00492	CbGeAlD
Risperidone—HTR1D—brain—acquired immunodeficiency syndrome	0.00029	0.0049	CbGeAlD
Risperidone—HTR2C—brain—acquired immunodeficiency syndrome	0.000288	0.00485	CbGeAlD
Risperidone—CYP3A5—blood—acquired immunodeficiency syndrome	0.000287	0.00484	CbGeAlD
Risperidone—DRD2—nervous system—acquired immunodeficiency syndrome	0.000286	0.00483	CbGeAlD
Risperidone—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000282	0.00476	CbGeAlD
Risperidone—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000281	0.00474	CbGeAlD
Risperidone—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000278	0.00469	CbGeAlD
Risperidone—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000276	0.00465	CbGeAlD
Risperidone—ADRA2A—blood—acquired immunodeficiency syndrome	0.000273	0.00461	CbGeAlD
Risperidone—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000271	0.00458	CbGeAlD
Risperidone—HTR2B—brain—acquired immunodeficiency syndrome	0.00027	0.00456	CbGeAlD
Risperidone—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000268	0.00452	CbGeAlD
Risperidone—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000266	0.00448	CbGeAlD
Risperidone—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000263	0.00444	CbGeAlD
Risperidone—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000261	0.0044	CbGeAlD
Risperidone—HRH1—vagina—acquired immunodeficiency syndrome	0.000258	0.00435	CbGeAlD
Risperidone—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000253	0.00428	CbGeAlD
Risperidone—CYP3A5—lung—acquired immunodeficiency syndrome	0.000251	0.00424	CbGeAlD
Risperidone—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000244	0.00412	CbGeAlD
Risperidone—HRH1—lung—acquired immunodeficiency syndrome	0.000244	0.00412	CbGeAlD
Risperidone—HTR1A—brain—acquired immunodeficiency syndrome	0.000242	0.00408	CbGeAlD
Risperidone—ADRA2A—lung—acquired immunodeficiency syndrome	0.00024	0.00404	CbGeAlD
Risperidone—HTR2A—blood—acquired immunodeficiency syndrome	0.000232	0.00392	CbGeAlD
Risperidone—HTR7—brain—acquired immunodeficiency syndrome	0.000231	0.0039	CbGeAlD
Risperidone—ABCB1—retina—acquired immunodeficiency syndrome	0.000228	0.00384	CbGeAlD
Risperidone—HRH1—nervous system—acquired immunodeficiency syndrome	0.000226	0.00381	CbGeAlD
Risperidone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000226	0.00381	CbGeAlD
Risperidone—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000224	0.00378	CbGeAlD
Risperidone—ADRA1A—brain—acquired immunodeficiency syndrome	0.000223	0.00376	CbGeAlD
Risperidone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000222	0.00375	CbGeAlD
Risperidone—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000222	0.00374	CbGeAlD
Risperidone—DRD2—brain—acquired immunodeficiency syndrome	0.000219	0.00369	CbGeAlD
Risperidone—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000218	0.00367	CbGeAlD
Risperidone—HTR2A—vagina—acquired immunodeficiency syndrome	0.000216	0.00364	CbGeAlD
Risperidone—KCNH2—brain—acquired immunodeficiency syndrome	0.000216	0.00364	CbGeAlD
Risperidone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000215	0.00363	CbGeAlD
Risperidone—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000214	0.0036	CbGeAlD
Risperidone—ADRA2C—brain—acquired immunodeficiency syndrome	0.000213	0.00359	CbGeAlD
Risperidone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000212	0.00357	CbGeAlD
Risperidone—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000208	0.00351	CbGeAlD
Risperidone—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000205	0.00347	CbGeAlD
Risperidone—HTR2A—lung—acquired immunodeficiency syndrome	0.000204	0.00344	CbGeAlD
Risperidone—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000189	0.00318	CbGeAlD
Risperidone—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000182	0.00307	CbGeAlD
Risperidone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000175	0.00295	CbGeAlD
Risperidone—HRH1—brain—acquired immunodeficiency syndrome	0.000173	0.00291	CbGeAlD
Risperidone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000172	0.0029	CbGeAlD
Risperidone—ADRA2A—brain—acquired immunodeficiency syndrome	0.00017	0.00286	CbGeAlD
Risperidone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000168	0.00284	CbGeAlD
Risperidone—HRH1—lymph node—acquired immunodeficiency syndrome	0.000167	0.00282	CbGeAlD
Risperidone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000166	0.00279	CbGeAlD
Risperidone—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000164	0.00277	CbGeAlD
Risperidone—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000162	0.00273	CbGeAlD
Risperidone—ABCB1—digestive system—acquired immunodeficiency syndrome	0.00016	0.0027	CbGeAlD
Risperidone—ABCB1—blood—acquired immunodeficiency syndrome	0.000152	0.00257	CbGeAlD
Risperidone—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000147	0.00249	CbGeAlD
Risperidone—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000147	0.00248	CbGeAlD
Risperidone—HTR2A—brain—acquired immunodeficiency syndrome	0.000144	0.00243	CbGeAlD
Risperidone—ABCB1—vagina—acquired immunodeficiency syndrome	0.000141	0.00238	CbGeAlD
Risperidone—ABCB1—lung—acquired immunodeficiency syndrome	0.000134	0.00225	CbGeAlD
Risperidone—CYP2D6—brain—acquired immunodeficiency syndrome	0.000131	0.00222	CbGeAlD
Risperidone—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000124	0.00209	CbGeAlD
Risperidone—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000119	0.00201	CbGeAlD
Risperidone—ABCB1—brain—acquired immunodeficiency syndrome	9.45e-05	0.00159	CbGeAlD
Risperidone—ABCB1—lymph node—acquired immunodeficiency syndrome	9.13e-05	0.00154	CbGeAlD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	6.22e-05	0.000238	CcSEcCtD
Risperidone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	6.2e-05	0.000237	CcSEcCtD
Risperidone—Pruritus—Abacavir—acquired immunodeficiency syndrome	6.2e-05	0.000237	CcSEcCtD
Risperidone—Fatigue—Indinavir—acquired immunodeficiency syndrome	6.2e-05	0.000237	CcSEcCtD
Risperidone—Anorexia—Delavirdine—acquired immunodeficiency syndrome	6.19e-05	0.000237	CcSEcCtD
Risperidone—Discomfort—Ritonavir—acquired immunodeficiency syndrome	6.19e-05	0.000237	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	6.19e-05	0.000237	CcSEcCtD
Risperidone—Cough—Saquinavir—acquired immunodeficiency syndrome	6.18e-05	0.000237	CcSEcCtD
Risperidone—Angioedema—Lamivudine—acquired immunodeficiency syndrome	6.18e-05	0.000236	CcSEcCtD
Risperidone—Pain—Indinavir—acquired immunodeficiency syndrome	6.15e-05	0.000235	CcSEcCtD
Risperidone—Constipation—Indinavir—acquired immunodeficiency syndrome	6.15e-05	0.000235	CcSEcCtD
Risperidone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	6.14e-05	0.000235	CcSEcCtD
Risperidone—Urticaria—Zidovudine—acquired immunodeficiency syndrome	6.14e-05	0.000235	CcSEcCtD
Risperidone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	6.14e-05	0.000235	CcSEcCtD
Risperidone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	6.13e-05	0.000234	CcSEcCtD
Risperidone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	6.12e-05	0.000234	CcSEcCtD
Risperidone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	6.11e-05	0.000234	CcSEcCtD
Risperidone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	6.11e-05	0.000234	CcSEcCtD
Risperidone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	6.1e-05	0.000233	CcSEcCtD
Risperidone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	6.1e-05	0.000233	CcSEcCtD
Risperidone—Malaise—Lamivudine—acquired immunodeficiency syndrome	6.1e-05	0.000233	CcSEcCtD
Risperidone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	6.08e-05	0.000233	CcSEcCtD
Risperidone—Nausea—Didanosine—acquired immunodeficiency syndrome	6.08e-05	0.000233	CcSEcCtD
Risperidone—Vertigo—Lamivudine—acquired immunodeficiency syndrome	6.07e-05	0.000232	CcSEcCtD
Risperidone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	6.07e-05	0.000232	CcSEcCtD
Risperidone—Syncope—Lamivudine—acquired immunodeficiency syndrome	6.06e-05	0.000232	CcSEcCtD
Risperidone—Confusional state—Ritonavir—acquired immunodeficiency syndrome	6.06e-05	0.000232	CcSEcCtD
Risperidone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	6.05e-05	0.000232	CcSEcCtD
Risperidone—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	6.05e-05	0.000231	CcSEcCtD
Risperidone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	6.04e-05	0.000231	CcSEcCtD
Risperidone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000231	CcSEcCtD
Risperidone—Chest pain—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000231	CcSEcCtD
Risperidone—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000231	CcSEcCtD
Risperidone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	6.01e-05	0.00023	CcSEcCtD
Risperidone—Oedema—Ritonavir—acquired immunodeficiency syndrome	6.01e-05	0.00023	CcSEcCtD
Risperidone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.99e-05	0.000229	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.99e-05	0.000229	CcSEcCtD
Risperidone—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	5.98e-05	0.000229	CcSEcCtD
Risperidone—Discomfort—Saquinavir—acquired immunodeficiency syndrome	5.96e-05	0.000228	CcSEcCtD
Risperidone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.94e-05	0.000227	CcSEcCtD
Risperidone—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	5.92e-05	0.000227	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.92e-05	0.000226	CcSEcCtD
Risperidone—Shock—Ritonavir—acquired immunodeficiency syndrome	5.91e-05	0.000226	CcSEcCtD
Risperidone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000226	CcSEcCtD
Risperidone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.9e-05	0.000226	CcSEcCtD
Risperidone—Cough—Lamivudine—acquired immunodeficiency syndrome	5.9e-05	0.000226	CcSEcCtD
Risperidone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.9e-05	0.000226	CcSEcCtD
Risperidone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.89e-05	0.000225	CcSEcCtD
Risperidone—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.88e-05	0.000225	CcSEcCtD
Risperidone—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.88e-05	0.000225	CcSEcCtD
Risperidone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.88e-05	0.000225	CcSEcCtD
Risperidone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.88e-05	0.000225	CcSEcCtD
Risperidone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.86e-05	0.000224	CcSEcCtD
Risperidone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.86e-05	0.000224	CcSEcCtD
Risperidone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000224	CcSEcCtD
Risperidone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.85e-05	0.000224	CcSEcCtD
Risperidone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.85e-05	0.000224	CcSEcCtD
Risperidone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.84e-05	0.000223	CcSEcCtD
Risperidone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.83e-05	0.000223	CcSEcCtD
Risperidone—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.83e-05	0.000223	CcSEcCtD
Risperidone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.81e-05	0.000222	CcSEcCtD
Risperidone—Pain—Efavirenz—acquired immunodeficiency syndrome	5.81e-05	0.000222	CcSEcCtD
Risperidone—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.81e-05	0.000222	CcSEcCtD
Risperidone—Rash—Nevirapine—acquired immunodeficiency syndrome	5.81e-05	0.000222	CcSEcCtD
Risperidone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.8e-05	0.000222	CcSEcCtD
Risperidone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.79e-05	0.000222	CcSEcCtD
Risperidone—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.79e-05	0.000222	CcSEcCtD
Risperidone—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.78e-05	0.000221	CcSEcCtD
Risperidone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	5.78e-05	0.000221	CcSEcCtD
Risperidone—Headache—Nevirapine—acquired immunodeficiency syndrome	5.77e-05	0.000221	CcSEcCtD
Risperidone—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.00022	CcSEcCtD
Risperidone—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.00022	CcSEcCtD
Risperidone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.00022	CcSEcCtD
Risperidone—Infection—Saquinavir—acquired immunodeficiency syndrome	5.74e-05	0.00022	CcSEcCtD
Risperidone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.73e-05	0.000219	CcSEcCtD
Risperidone—Anorexia—Ritonavir—acquired immunodeficiency syndrome	5.73e-05	0.000219	CcSEcCtD
Risperidone—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5.72e-05	0.000219	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.72e-05	0.000219	CcSEcCtD
Risperidone—Urticaria—Indinavir—acquired immunodeficiency syndrome	5.71e-05	0.000218	CcSEcCtD
Risperidone—Shock—Saquinavir—acquired immunodeficiency syndrome	5.69e-05	0.000218	CcSEcCtD
Risperidone—Discomfort—Lamivudine—acquired immunodeficiency syndrome	5.69e-05	0.000218	CcSEcCtD
Risperidone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.68e-05	0.000217	CcSEcCtD
Risperidone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.68e-05	0.000217	CcSEcCtD
Risperidone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.67e-05	0.000217	CcSEcCtD
Risperidone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.67e-05	0.000217	CcSEcCtD
Risperidone—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.66e-05	0.000217	CcSEcCtD
Risperidone—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.65e-05	0.000216	CcSEcCtD
Risperidone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.65e-05	0.000216	CcSEcCtD
Risperidone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.63e-05	0.000215	CcSEcCtD
Risperidone—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.62e-05	0.000215	CcSEcCtD
Risperidone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.62e-05	0.000215	CcSEcCtD
Risperidone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.62e-05	0.000215	CcSEcCtD
Risperidone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.61e-05	0.000215	CcSEcCtD
Risperidone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.61e-05	0.000215	CcSEcCtD
Risperidone—Rash—Stavudine—acquired immunodeficiency syndrome	5.61e-05	0.000214	CcSEcCtD
Risperidone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.6e-05	0.000214	CcSEcCtD
Risperidone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.6e-05	0.000214	CcSEcCtD
Risperidone—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.6e-05	0.000214	CcSEcCtD
Risperidone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.59e-05	0.000214	CcSEcCtD
Risperidone—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.59e-05	0.000214	CcSEcCtD
Risperidone—Headache—Stavudine—acquired immunodeficiency syndrome	5.57e-05	0.000213	CcSEcCtD
Risperidone—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.57e-05	0.000213	CcSEcCtD
Risperidone—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.56e-05	0.000213	CcSEcCtD
Risperidone—Pain—Delavirdine—acquired immunodeficiency syndrome	5.56e-05	0.000213	CcSEcCtD
Risperidone—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.56e-05	0.000213	CcSEcCtD
Risperidone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.55e-05	0.000212	CcSEcCtD
Risperidone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.54e-05	0.000212	CcSEcCtD
Risperidone—Rash—Abacavir—acquired immunodeficiency syndrome	5.52e-05	0.000211	CcSEcCtD
Risperidone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5.52e-05	0.000211	CcSEcCtD
Risperidone—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.000211	CcSEcCtD
Risperidone—Oedema—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.000211	CcSEcCtD
Risperidone—Anorexia—Saquinavir—acquired immunodeficiency syndrome	5.51e-05	0.000211	CcSEcCtD
Risperidone—Headache—Abacavir—acquired immunodeficiency syndrome	5.49e-05	0.00021	CcSEcCtD
Risperidone—Infection—Lamivudine—acquired immunodeficiency syndrome	5.48e-05	0.00021	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	5.47e-05	0.000209	CcSEcCtD
Risperidone—Nausea—Nevirapine—acquired immunodeficiency syndrome	5.47e-05	0.000209	CcSEcCtD
Risperidone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	5.47e-05	0.000209	CcSEcCtD
Risperidone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	5.43e-05	0.000208	CcSEcCtD
Risperidone—Shock—Lamivudine—acquired immunodeficiency syndrome	5.43e-05	0.000208	CcSEcCtD
Risperidone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	5.41e-05	0.000207	CcSEcCtD
Risperidone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	5.4e-05	0.000207	CcSEcCtD
Risperidone—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	5.4e-05	0.000207	CcSEcCtD
Risperidone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	5.39e-05	0.000206	CcSEcCtD
Risperidone—Urticaria—Efavirenz—acquired immunodeficiency syndrome	5.39e-05	0.000206	CcSEcCtD
Risperidone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	5.37e-05	0.000205	CcSEcCtD
Risperidone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	5.37e-05	0.000205	CcSEcCtD
Risperidone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	5.36e-05	0.000205	CcSEcCtD
Risperidone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	5.36e-05	0.000205	CcSEcCtD
Risperidone—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	5.35e-05	0.000205	CcSEcCtD
Risperidone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	5.34e-05	0.000204	CcSEcCtD
Risperidone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.33e-05	0.000204	CcSEcCtD
Risperidone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.31e-05	0.000203	CcSEcCtD
Risperidone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.3e-05	0.000203	CcSEcCtD
Risperidone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.3e-05	0.000203	CcSEcCtD
Risperidone—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.29e-05	0.000202	CcSEcCtD
Risperidone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.29e-05	0.000202	CcSEcCtD
Risperidone—Nausea—Stavudine—acquired immunodeficiency syndrome	5.28e-05	0.000202	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.000202	CcSEcCtD
Risperidone—Anorexia—Lamivudine—acquired immunodeficiency syndrome	5.26e-05	0.000201	CcSEcCtD
Risperidone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.23e-05	0.0002	CcSEcCtD
Risperidone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.0002	CcSEcCtD
Risperidone—Nausea—Abacavir—acquired immunodeficiency syndrome	5.2e-05	0.000199	CcSEcCtD
Risperidone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.19e-05	0.000199	CcSEcCtD
Risperidone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.19e-05	0.000198	CcSEcCtD
Risperidone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.18e-05	0.000198	CcSEcCtD
Risperidone—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.16e-05	0.000197	CcSEcCtD
Risperidone—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.16e-05	0.000197	CcSEcCtD
Risperidone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.16e-05	0.000197	CcSEcCtD
Risperidone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.15e-05	0.000197	CcSEcCtD
Risperidone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	5.14e-05	0.000197	CcSEcCtD
Risperidone—Pain—Ritonavir—acquired immunodeficiency syndrome	5.14e-05	0.000197	CcSEcCtD
Risperidone—Constipation—Ritonavir—acquired immunodeficiency syndrome	5.14e-05	0.000197	CcSEcCtD
Risperidone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.14e-05	0.000196	CcSEcCtD
Risperidone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.14e-05	0.000196	CcSEcCtD
Risperidone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.11e-05	0.000195	CcSEcCtD
Risperidone—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	5.09e-05	0.000195	CcSEcCtD
Risperidone—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.08e-05	0.000195	CcSEcCtD
Risperidone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.03e-05	0.000192	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000192	CcSEcCtD
Risperidone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5e-05	0.000191	CcSEcCtD
Risperidone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000191	CcSEcCtD
Risperidone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.99e-05	0.000191	CcSEcCtD
Risperidone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000191	CcSEcCtD
Risperidone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.95e-05	0.00019	CcSEcCtD
Risperidone—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.95e-05	0.000189	CcSEcCtD
Risperidone—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.95e-05	0.000189	CcSEcCtD
Risperidone—Pain—Saquinavir—acquired immunodeficiency syndrome	4.95e-05	0.000189	CcSEcCtD
Risperidone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.92e-05	0.000188	CcSEcCtD
Risperidone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.92e-05	0.000188	CcSEcCtD
Risperidone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.91e-05	0.000188	CcSEcCtD
Risperidone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.91e-05	0.000188	CcSEcCtD
Risperidone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.9e-05	0.000188	CcSEcCtD
Risperidone—Rash—Zidovudine—acquired immunodeficiency syndrome	4.87e-05	0.000186	CcSEcCtD
Risperidone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.87e-05	0.000186	CcSEcCtD
Risperidone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.87e-05	0.000186	CcSEcCtD
Risperidone—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.86e-05	0.000186	CcSEcCtD
Risperidone—Headache—Zidovudine—acquired immunodeficiency syndrome	4.84e-05	0.000185	CcSEcCtD
Risperidone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.8e-05	0.000184	CcSEcCtD
Risperidone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.8e-05	0.000183	CcSEcCtD
Risperidone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.79e-05	0.000183	CcSEcCtD
Risperidone—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.77e-05	0.000183	CcSEcCtD
Risperidone—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.77e-05	0.000182	CcSEcCtD
Risperidone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.000182	CcSEcCtD
Risperidone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.000182	CcSEcCtD
Risperidone—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.75e-05	0.000182	CcSEcCtD
Risperidone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.75e-05	0.000182	CcSEcCtD
Risperidone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.75e-05	0.000182	CcSEcCtD
Risperidone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.73e-05	0.000181	CcSEcCtD
Risperidone—Pain—Lamivudine—acquired immunodeficiency syndrome	4.72e-05	0.00018	CcSEcCtD
Risperidone—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.72e-05	0.00018	CcSEcCtD
Risperidone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.66e-05	0.000178	CcSEcCtD
Risperidone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.65e-05	0.000178	CcSEcCtD
Risperidone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.6e-05	0.000176	CcSEcCtD
Risperidone—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.59e-05	0.000176	CcSEcCtD
Risperidone—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.59e-05	0.000176	CcSEcCtD
Risperidone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.57e-05	0.000175	CcSEcCtD
Risperidone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.57e-05	0.000175	CcSEcCtD
Risperidone—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.57e-05	0.000175	CcSEcCtD
Risperidone—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.55e-05	0.000174	CcSEcCtD
Risperidone—Rash—Indinavir—acquired immunodeficiency syndrome	4.53e-05	0.000173	CcSEcCtD
Risperidone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.53e-05	0.000173	CcSEcCtD
Risperidone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.51e-05	0.000173	CcSEcCtD
Risperidone—Headache—Indinavir—acquired immunodeficiency syndrome	4.5e-05	0.000172	CcSEcCtD
Risperidone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.49e-05	0.000172	CcSEcCtD
Risperidone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.45e-05	0.00017	CcSEcCtD
Risperidone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.43e-05	0.000169	CcSEcCtD
Risperidone—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.38e-05	0.000168	CcSEcCtD
Risperidone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.36e-05	0.000167	CcSEcCtD
Risperidone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.36e-05	0.000167	CcSEcCtD
Risperidone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.32e-05	0.000165	CcSEcCtD
Risperidone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.31e-05	0.000165	CcSEcCtD
Risperidone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.3e-05	0.000164	CcSEcCtD
Risperidone—Rash—Efavirenz—acquired immunodeficiency syndrome	4.28e-05	0.000164	CcSEcCtD
Risperidone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.28e-05	0.000164	CcSEcCtD
Risperidone—Nausea—Indinavir—acquired immunodeficiency syndrome	4.27e-05	0.000163	CcSEcCtD
Risperidone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.26e-05	0.000163	CcSEcCtD
Risperidone—Headache—Efavirenz—acquired immunodeficiency syndrome	4.25e-05	0.000163	CcSEcCtD
Risperidone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.25e-05	0.000163	CcSEcCtD
Risperidone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.15e-05	0.000159	CcSEcCtD
Risperidone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.13e-05	0.000158	CcSEcCtD
Risperidone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.11e-05	0.000157	CcSEcCtD
Risperidone—Rash—Delavirdine—acquired immunodeficiency syndrome	4.1e-05	0.000157	CcSEcCtD
Risperidone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.09e-05	0.000157	CcSEcCtD
Risperidone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.09e-05	0.000157	CcSEcCtD
Risperidone—Headache—Delavirdine—acquired immunodeficiency syndrome	4.07e-05	0.000156	CcSEcCtD
Risperidone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.06e-05	0.000155	CcSEcCtD
Risperidone—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.03e-05	0.000154	CcSEcCtD
Risperidone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.97e-05	0.000152	CcSEcCtD
Risperidone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.96e-05	0.000151	CcSEcCtD
Risperidone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.96e-05	0.000151	CcSEcCtD
Risperidone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.9e-05	0.000149	CcSEcCtD
Risperidone—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.86e-05	0.000148	CcSEcCtD
Risperidone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.82e-05	0.000146	CcSEcCtD
Risperidone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.82e-05	0.000146	CcSEcCtD
Risperidone—Rash—Ritonavir—acquired immunodeficiency syndrome	3.79e-05	0.000145	CcSEcCtD
Risperidone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.78e-05	0.000145	CcSEcCtD
Risperidone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.77e-05	0.000144	CcSEcCtD
Risperidone—Headache—Ritonavir—acquired immunodeficiency syndrome	3.76e-05	0.000144	CcSEcCtD
Risperidone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.68e-05	0.000141	CcSEcCtD
Risperidone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.65e-05	0.00014	CcSEcCtD
Risperidone—Rash—Saquinavir—acquired immunodeficiency syndrome	3.65e-05	0.000139	CcSEcCtD
Risperidone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.64e-05	0.000139	CcSEcCtD
Risperidone—Headache—Saquinavir—acquired immunodeficiency syndrome	3.62e-05	0.000139	CcSEcCtD
Risperidone—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.57e-05	0.000137	CcSEcCtD
Risperidone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.51e-05	0.000134	CcSEcCtD
Risperidone—Rash—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000133	CcSEcCtD
Risperidone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000133	CcSEcCtD
Risperidone—Headache—Lamivudine—acquired immunodeficiency syndrome	3.46e-05	0.000132	CcSEcCtD
Risperidone—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.43e-05	0.000131	CcSEcCtD
Risperidone—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.28e-05	0.000125	CcSEcCtD
Risperidone—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.77e-05	0.000351	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.76e-05	0.000349	CbGpPWpGaD
Risperidone—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.75e-05	0.000348	CbGpPWpGaD
Risperidone—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.74e-05	0.000346	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.74e-05	0.000346	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.000344	CbGpPWpGaD
Risperidone—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.73e-05	0.000344	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.71e-05	0.00034	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.71e-05	0.000339	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.7e-05	0.000337	CbGpPWpGaD
Risperidone—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.69e-05	0.000337	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.69e-05	0.000336	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.69e-05	0.000336	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.000335	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.000334	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.000334	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.000334	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.000333	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.67e-05	0.000333	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.67e-05	0.000332	CbGpPWpGaD
Risperidone—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.67e-05	0.000332	CbGpPWpGaD
Risperidone—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	1.66e-05	0.00033	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.66e-05	0.000329	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.65e-05	0.000329	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.65e-05	0.000328	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.65e-05	0.000328	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.64e-05	0.000327	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.62e-05	0.000322	CbGpPWpGaD
Risperidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.61e-05	0.000321	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.61e-05	0.000321	CbGpPWpGaD
Risperidone—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.61e-05	0.00032	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.000319	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.59e-05	0.000317	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.59e-05	0.000317	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.59e-05	0.000316	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.000315	CbGpPWpGaD
Risperidone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.58e-05	0.000314	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.57e-05	0.000313	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.57e-05	0.000313	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.56e-05	0.00031	CbGpPWpGaD
Risperidone—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	1.55e-05	0.000309	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.55e-05	0.000308	CbGpPWpGaD
Risperidone—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	1.55e-05	0.000308	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.000306	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.000306	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.54e-05	0.000306	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.54e-05	0.000305	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.53e-05	0.000304	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.000304	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.52e-05	0.000303	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.52e-05	0.000303	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.000301	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.000301	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.51e-05	0.0003	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.0003	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.5e-05	0.000299	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.5e-05	0.000299	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.5e-05	0.000298	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.49e-05	0.000297	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.48e-05	0.000295	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.47e-05	0.000292	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.46e-05	0.00029	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.45e-05	0.000288	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.42e-05	0.000282	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.42e-05	0.000282	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.42e-05	0.000281	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.41e-05	0.00028	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.41e-05	0.00028	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.4e-05	0.000278	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000278	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.39e-05	0.000277	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.39e-05	0.000276	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.39e-05	0.000276	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.39e-05	0.000276	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.39e-05	0.000276	CbGpPWpGaD
Risperidone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.38e-05	0.000275	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.000274	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.38e-05	0.000274	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.37e-05	0.000273	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.37e-05	0.000273	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.37e-05	0.000273	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.37e-05	0.000273	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.37e-05	0.000272	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.37e-05	0.000272	CbGpPWpGaD
Risperidone—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.37e-05	0.000271	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.000271	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.000271	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.36e-05	0.000271	CbGpPWpGaD
Risperidone—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.36e-05	0.00027	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.35e-05	0.000268	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.35e-05	0.000268	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.35e-05	0.000267	CbGpPWpGaD
Risperidone—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000264	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.33e-05	0.000264	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.33e-05	0.000264	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.33e-05	0.000264	CbGpPWpGaD
Risperidone—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.31e-05	0.00026	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.31e-05	0.00026	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.31e-05	0.00026	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.31e-05	0.00026	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.29e-05	0.000256	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.28e-05	0.000255	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.000252	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.27e-05	0.000252	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.27e-05	0.000252	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.26e-05	0.00025	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.26e-05	0.00025	CbGpPWpGaD
Risperidone—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	1.26e-05	0.00025	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.26e-05	0.00025	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.25e-05	0.000249	CbGpPWpGaD
Risperidone—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.25e-05	0.000248	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000247	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.23e-05	0.000245	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000245	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.23e-05	0.000245	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.000241	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.000241	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.21e-05	0.00024	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.2e-05	0.000239	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.2e-05	0.000239	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.2e-05	0.000238	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.000237	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.19e-05	0.000236	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.18e-05	0.000235	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.18e-05	0.000235	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.18e-05	0.000235	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.18e-05	0.000235	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.000234	CbGpPWpGaD
Risperidone—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.18e-05	0.000234	CbGpPWpGaD
Risperidone—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000231	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.16e-05	0.000231	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.16e-05	0.000231	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.00023	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.15e-05	0.000228	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000225	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.000217	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.08e-05	0.000215	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.000214	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.08e-05	0.000214	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.08e-05	0.000214	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.07e-05	0.000212	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.000212	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.05e-05	0.00021	CbGpPWpGaD
Risperidone—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000208	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000207	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000206	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.03e-05	0.000204	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000203	CbGpPWpGaD
Risperidone—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000201	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.01e-05	0.000201	CbGpPWpGaD
Risperidone—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.01e-05	0.0002	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.94e-06	0.000198	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.93e-06	0.000197	CbGpPWpGaD
Risperidone—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.79e-06	0.000195	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.78e-06	0.000194	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.73e-06	0.000193	CbGpPWpGaD
Risperidone—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.64e-06	0.000192	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.52e-06	0.000189	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.39e-06	0.000187	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.35e-06	0.000186	CbGpPWpGaD
Risperidone—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.29e-06	0.000185	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.19e-06	0.000183	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.16e-06	0.000182	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.14e-06	0.000182	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.09e-06	0.000181	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.02e-06	0.000179	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.01e-06	0.000179	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.99e-06	0.000179	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.95e-06	0.000178	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.89e-06	0.000177	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.88e-06	0.000177	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.87e-06	0.000176	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.85e-06	0.000176	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.82e-06	0.000175	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.75e-06	0.000174	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.74e-06	0.000174	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.72e-06	0.000173	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.69e-06	0.000173	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.56e-06	0.00017	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.25e-06	0.000164	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.2e-06	0.000163	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.12e-06	0.000161	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.1e-06	0.000161	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.07e-06	0.000161	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.07e-06	0.00016	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	7.98e-06	0.000159	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.95e-06	0.000158	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.95e-06	0.000158	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.94e-06	0.000158	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.92e-06	0.000157	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.77e-06	0.000155	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	7.75e-06	0.000154	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.38e-06	0.000147	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.32e-06	0.000146	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.29e-06	0.000145	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.28e-06	0.000145	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.24e-06	0.000144	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.22e-06	0.000144	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.13e-06	0.000142	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.09e-06	0.000141	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.01e-06	0.000139	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.98e-06	0.000139	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.69e-06	0.000133	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.66e-06	0.000132	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.31e-06	0.000126	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	6.29e-06	0.000125	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.28e-06	0.000125	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.23e-06	0.000124	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.2e-06	0.000123	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	5.77e-06	0.000115	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.62e-06	0.000112	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.59e-06	0.000111	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.43e-06	0.000108	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.4e-06	0.000107	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.4e-06	0.000107	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.37e-06	0.000107	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.25e-06	0.000104	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.23e-06	0.000104	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.17e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.14e-06	0.000102	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.77e-06	9.48e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.74e-06	9.43e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.69e-06	9.32e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.68e-06	9.3e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.67e-06	9.28e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.66e-06	9.26e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.59e-06	9.13e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.57e-06	9.08e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.35e-06	8.65e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.31e-06	8.56e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.28e-06	8.5e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.27e-06	8.48e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.24e-06	8.44e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.19e-06	8.33e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.12e-06	8.19e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.1e-06	8.15e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.93e-06	7.82e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.71e-06	7.38e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.66e-06	7.28e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.3e-06	6.57e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.19e-06	6.34e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.17e-06	6.31e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.09e-06	6.14e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.04e-06	6.04e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.8e-06	5.57e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.76e-06	5.48e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.75e-06	5.47e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.7e-06	5.37e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.68e-06	5.33e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.51e-06	4.99e-05	CbGpPWpGaD
